Charting a course for global progress in PIDs by 2030 — proceedings from the IPOPI global multi-stakeholders’ summit (September 2023)

The IPOPI Global Multi-Stakeholders’ Summit in 2023 marked a pivotal moment for the Primary Immunodeficiency (PID) community, fostering forward-thinking discussions among stakeholders to shape the future priorities of PID care. In this article, we’re excited to share the comprehensive recommendations that emerged from this groundbreaking summit.

From pandemic preparedness to artificial intelligence tools

During the summit, various topics were discussed, including:

• Personalised patient needs in immunoglobulin (Ig) therapy: This session explored avenues to improve Ig therapy through mechanistic insights and tailored Ig preparations or products according to patient-specific needs and local exposure to infectious agents, amongst others.
• Pandemic preparedness: Reflections and lessons learned from the COVID-19 pandemic and the threat of antibiotics shortages and increasing antimicrobial resistance emphasized the need for representation of PID patients and other vulnerable populations throughout crisis and care management.
• Diagnostic opportunities: Discussion also covered the complexities of PID diagnosis, addressing issues such as global diagnostic disparities, the integration of patient-reported outcome measures, and the potential of artificial intelligence to increase PID diagnosis rates and to enhance diagnostic precision.

Experts, physicians, scientists, patients, and representatives from across the globe came together during the summit to discuss the environment for PID patients in the upcoming decade. Through this collaborative effort, we aim to pave the way for improved PID diagnosis and care, by building upon the shared understanding of challenges, opportunities, and scenarios discussed during the summit.

Read the full article here.

This meeting was made possible thanks to the support from CSL Behring, Grifols and Takeda.